First Drug-Coated Balloon IDE: A Conversation With Lutonix CEO Dennis Wahr
This article was originally published in The Gray Sheet
Executive Summary
Following a four-year effort with FDA, Minneapolis start-up Lutonix recently met its goal to become the first company to gain an investigational device exemption for a drug-coated balloon.
You may also be interested in...
Bard Buys Lutonix For Lead In Race To U.S. Market With Drug-Coated Balloon
Deal worth up to $325 million makes Bard first in line to enter the U.S. market with a drug-coated balloon. Firm anticipates PMA submission for Moxy in 2014.
Lutonix: Back To The Future With Drug-Coated Balloons
Drug-coated balloons were once thought to be an unnecessary innovation because of drug-eluting stents. With DES no longer seen as the panacea for vascular disease, balloons could re-emerge as the next major technology platform, and Lutonix is leading the race to bring them to the US market.
Cook Medical Makes Progress In Peripheral Stent Space
Cook Medical is making advances in the peripheral stent market with the imminent launch of its Formula balloon-expandable renal stent system, and a recent report of two-year data for its PMA-pending Zilver PTX paclitaxel-eluting stent.